Nuveen
EVLO

Nuveen’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Nuveen’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,809
Closed -$310K – 3576
2022
Q1 		$310K Buy
4,809
+80
+2% +$6.66K ﹤0.01% 3119
2021
Q4 		$685K Sell
4,729
-348
-7% -$58.8K ﹤0.01% 2981
2021
Q3 		$847K Sell
5,077
-343
-6% -$68K ﹤0.01% 3048
2021
Q2 		$1.49M Buy
5,420
+2,095
+63% +$529K ﹤0.01% 2842
2021
Q1 		$712K Buy
3,325
+542
+19% +$150K ﹤0.01% 3002
2020
Q4 		$672K Buy
2,783
+279
+11% +$34.5K ﹤0.01% 2943
2020
Q3 		$264K Buy
2,504
+876
+54% +$79.8K ﹤0.01% 3108
2020
Q2 		$160K Sell
1,628
-210
-11% -$18.4K ﹤0.01% 3127
2020
Q1 		$138K Buy
1,838
+118
+7% +$11.2K ﹤0.01% 3042
2019
Q4 		$140K Hold
1,720
– – ﹤0.01% 3102
2019
Q3 		$210K Sell
1,720
-125
-7% -$17.2K ﹤0.01% 3116
2019
Q2 		$331K Buy
+1,845
New +$298K ﹤0.01% 3104

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's EVLO Position: Q2 2022 in Review

Nuveen sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2022, closing a stake of 4,809 shares — an estimated $310K sold.

Nuveen first reported a position in EVLO in Q2 2019 and held it in 12 quarters. The position peaked at $1.49M in Q2 2021. 46 funds tracked by Wall St. Rank hold EVLO as of Q2 2022.

  • Nuveen reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 4,809 Evelo Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $310K.
  • Nuveen first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Nuveen's Evelo Biosciences, Inc. Common Stock position peaked at $1.49M in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.